Safety and tolerability of cell culture-derived and egg-derived trivalent influenza vaccines in 3 to <18-year-old children and adolescents at risk of influenza-related complications. (August 2016)

• Record Type: Journal Article
• Authors: Diez-Domingo, Javier; de Martino, Maurizio; Lopez, Jose Garcia-Sicilia; Zuccotti, Gian Vincenzo; Icardi, Giancarlo; Villani, Alberto; Moreno-Perez, David; Hernández, María Méndez; Aldeán, Javier Álvarez; Mateen, Ahmed Abdul; Enweonye, Igwebuike; de Rooij, Richard; Chandra, Richa
• Is Part Of: International journal of infectious diseases. Volume 49(2016:Aug.)
• Page Start: 171
• Page End: 178
• Publication Date: 2016-08
• Subjects: Safety -- Cell culture-derived -- Influenza vaccine -- At-risk children; Communicable diseases -- Periodicals; Communicable Diseases -- Periodicals; Communicable diseases; Periodicals; Electronic journals; 616.9
• DOI: 10.1016/j.ijid.2016.06.018
• Languages: English
• ISSNs: 1201-9712

Abstract

Highlights: This is the first study to assess the safety of cell-derived vaccine in at-risk children. The cell culture-derived (TIVc) and egg-derived (TIV) trivalent influenza vaccines were generally well tolerated in children at risk of influenza. The TIVc and TIV had similar safety profiles in children at risk of influenza. There were no cases of severe fever or serious adverse events (AEs) with either TIVc or TIV. The most common solicited AEs were pain, irritability, and headache. Summary: Background: This descriptive, non-comparative, phase III study evaluated the safety and tolerability of cell culture-derived (TIVc) and egg-derived (TIV) seasonal influenza vaccines in children at risk of influenza-related complications. Methods: Four hundred and thirty subjects were randomized 2:1 to TIVc or TIV. Subjects aged 3 to &lt;9 years received one dose (if previously vaccinated, n = 89) or two doses (if not previously vaccinated, n = 124) of the study vaccines; the 9 to &lt;18-year-olds ( n = 213) received one dose. Reactogenicity was assessed for 7 days after vaccination; safety was monitored for 6 months. Results: After any vaccination, the most frequently reported solicited local adverse event (AE) was tenderness/pain (TIVc 44%, 66%, 53% and TIV 56%, 51%, 65% in the age groups 3 to &lt;6 years, 6 to &lt;9 years, and 9 to &lt;18 years, respectively) and the systemic AE was irritability (22% TIVc, 24% TIV) in 3 to &lt;6-year-olds and headache in 6 to &lt;9-year-olds (20% TIVc, 13% TIV) and 9 to &lt;18-year-olds (21% TIVc, 26% TIV). There were no cases of severe fever (≥40 °C). No vaccine-related serious AEs were noted. New onset of chronic disease was reported in ≤1% of subjects. Conclusion: TIVc and TIV had acceptable tolerability and similar safety profiles in at-risk children (NCT01998477 ).